Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.
da Penha Gomes Gouvea M, Lira Machado KLL, de Oliveira YGP, Moulaz IR, Henriques AG, Gouveia TM, Thompson BP, Lança KEM, de Souza Ramos S, Lacerda GCC, Lenzi JPG, de Castro Pimentel F, Miossi JPM, Rassele ML, Camacho LAB, Villela DAM, de Lima SMB, de Souza Azevedo A, Horbach IS, de Araújo MF, Tort LFL, de Oliveira ACA, Siqueira MM, Garcia CC, da Costa-Rocha IA, Campi-Azevedo AC, Peruhype-Magalhães V, da Silva VG, Miyamoto ST, Dos Santos Fantoni RN, Pinto-Neto LF, Magda Domingues C, de Medeiros Junior NF, Burian AP, Teixeira-Carvalho A, Mota LMH, Mill JG, Martins-Filho OA, Valim V. da Penha Gomes Gouvea M, et al. Among authors: de lima smb. Vaccine. 2023 Oct 20;41(44):6514-6528. doi: 10.1016/j.vaccine.2023.08.022. Epub 2023 Sep 1. Vaccine. 2023. PMID: 37661534
Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study.
de Menezes Martins R, Maia MLS, de Lima SMB, de Noronha TG, Xavier JR, Camacho LAB, de Albuquerque EM, Farias RHG, da Matta de Castro T, Homma A; Collaborative Group for Studies on Duration of Immunity from Yellow Fever Vaccine. de Menezes Martins R, et al. Among authors: de noronha tg, de albuquerque em, de lima smb. Vaccine. 2018 Jun 27;36(28):4112-4117. doi: 10.1016/j.vaccine.2018.05.041. Epub 2018 May 18. Vaccine. 2018. PMID: 29784469 Free PMC article.
Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.
Ferreira CC, Campi-Azevedo AC, Peruhype-Magalhāes V, Coelho-Dos-Reis JG, Antonelli LRDV, Torres K, Freire LC, da Costa-Rocha IA, Oliveira ACV, Maia MLS, de Lima SMB, Domingues CM, Teixeira-Carvalho A, Martins-Filho OA, da Mota LMH; Collaborative Group for Studies of Yellow Fever Vaccine. Ferreira CC, et al. Among authors: de lima smb. Arthritis Res Ther. 2019 Mar 14;21(1):75. doi: 10.1186/s13075-019-1854-6. Arthritis Res Ther. 2019. PMID: 30871593 Free PMC article. Clinical Trial.
Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.
da Costa-Rocha IA, Campi-Azevedo AC, Peruhype-Magalhães V, Coelho-Dos-Reis JG, Fradico JRB, Souza-Lopes T, Reis LR, Freire LC, Costa-Pereira C, Mambrini JVM, Maia MLS, de Lima SMB, de Noronha TG, Xavier JR, Camacho LAB, de Albuquerque EM, Farias RHG, de Castro TDM, Homma A, Romano APM, Domingues CM, Martins RM, Teixeira-Carvalho A, Martins-Filho OA. da Costa-Rocha IA, et al. Among authors: de noronha tg, de castro tdm, de albuquerque em, de lima smb. Front Immunol. 2019 Jun 21;10:1211. doi: 10.3389/fimmu.2019.01211. eCollection 2019. Front Immunol. 2019. PMID: 31293563 Free PMC article. Clinical Trial.
Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
Campi-Azevedo AC, Reis LR, Peruhype-Magalhães V, Coelho-Dos-Reis JG, Antonelli LR, Fonseca CT, Costa-Pereira C, Souza-Fagundes EM, da Costa-Rocha IA, Mambrini JVM, Lemos JAC, Ribeiro JGL, Caldas IR, Camacho LAB, Maia MLS, de Noronha TG, de Lima SMB, Simões M, Freire MDS, Martins RM, Homma A, Tauil PL, Vasconcelos PFC, Romano APM, Domingues CM, Teixeira-Carvalho A, Martins-Filho OA. Campi-Azevedo AC, et al. Among authors: de noronha tg, de lima smb. Front Immunol. 2019 Sep 26;10:2192. doi: 10.3389/fimmu.2019.02192. eCollection 2019. Front Immunol. 2019. PMID: 31616412 Free PMC article. Clinical Trial.
Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.
da Costa-Rocha IA, Campi-Azevedo AC, Peruhype-Magalhães V, Coelho-Dos-Reis JG, Fradico JRB, Souza-Lopes T, Reis LR, Freire LC, Costa-Pereira C, Mambrini JVM, Maia MLS, de Lima SMB, de Noronha TG, Xavier JR, Camacho LAB, de Albuquerque EM, Farias RHG, de Castro TDM, Homma A, Romano APM, Domingues CM, Martins RM, Teixeira-Carvalho A, Martins-Filho OA. da Costa-Rocha IA, et al. Among authors: de noronha tg, de castro tdm, de albuquerque em, de lima smb. Front Immunol. 2019 Oct 22;10:2433. doi: 10.3389/fimmu.2019.02433. eCollection 2019. Front Immunol. 2019. PMID: 31695694 Free PMC article.
Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.
Valim V, Machado KLLL, Miyamoto ST, Pinto AD, Rocha PCM, Serrano EV, Dinis VG, Gouvêa SA, Dias JGF, Campi-Azevedo AC, Teixeira-Carvalho A, Peruhype-Magalhães V, da Costa-Rocha IA, de Lima SMB, Miranda EH, Trindade GF, Maia MLS, Gavi MBRO, da Silva LB, Duque RH, Gianordoli APE, Casagrande TZ, Oliveira KG, Moura BCDM, Nicole-Batista F, Rodrigues LC, Clemente TB, Magalhães ES, Bissoli MF, Gouvea MDPG, Pinto-Neto LFDS, Costa CZ, Giovelli RA, Brandão LR, Polito ETL, Koehlert IO, Borjaille BP, Pereira DB, Dias LH, Merlo DL, Genelhu LFF, Pretti FZ, Giacomin MDS, Burian APN, Fantinato FFST, Pileggi GS, da Mota LMH, Martins-Filho OA. Valim V, et al. Among authors: de lima smb. Front Immunol. 2020 Jul 17;11:1382. doi: 10.3389/fimmu.2020.01382. eCollection 2020. Front Immunol. 2020. PMID: 32765496 Free PMC article.
Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals.
Bonin CRB, Fernandes GC, de Menezes Martins R, Camacho LAB, Teixeira-Carvalho A, da Mota LMH, de Lima SMB, Campi-Azevedo AC, Martins-Filho OA, Dos Santos RW, Lobosco M; Collaborative Group for Studies of Yellow Fever Vaccine. Bonin CRB, et al. Among authors: de lima smb, de menezes martins r. BMC Bioinformatics. 2020 Dec 14;21(Suppl 17):551. doi: 10.1186/s12859-020-03845-3. BMC Bioinformatics. 2020. PMID: 33308151 Free PMC article.
Molecular and Cellular Biomarkers of COVID-19 Prognosis: Protocol for the Prospective Cohort TARGET Study.
Kurizky P, Nóbrega OT, Soares AASM, Aires RB, Albuquerque CP, Nicola AM, Albuquerque P, Teixeira-Carvalho A, Naves LA, Fontes W, Luz IS, Felicori L, Gomides APM, Mendonça-Silva DL, Espindola LS, Martins-Filho OA, de Lima SMB, Mota LMH, Gomes CM. Kurizky P, et al. Among authors: de lima smb. JMIR Res Protoc. 2021 Mar 4;10(3):e24211. doi: 10.2196/24211. JMIR Res Protoc. 2021. PMID: 33661132 Free PMC article.
Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
da Costa-Rocha IA, Machado KLLL, Campi-Azevedo AC, Teixeira-Carvalho A, Peruhype-Magalhães V, de Lima SMB, Miranda EH, Trindade GF, Casagrande TZ, Miyamoto ST, Deotti SC, Barbosa RVR, Rocha PCM, Serrano EV, Dinis VG, Gouvêa SA, Gavi MBRO, da Silva LB, Duque RH, Gianordoli APE, Bissoli MF, Gouvea MDPG, Pinto-Neto LFDS, Burian APN, Fantinato FFST, Pileggi GS, da Mota LMH, Valim V, Martins-Filho OA. da Costa-Rocha IA, et al. Among authors: de lima smb. Sci Rep. 2021 May 17;11(1):10431. doi: 10.1038/s41598-021-89770-8. Sci Rep. 2021. PMID: 34001945 Free PMC article.
27 results